Valsts: Singapūra
Valoda: angļu
Klimata pārmaiņas: HSA (Health Sciences Authority)
FLUDROCORTISONE ACETATE
DCH AURIGA SINGAPORE
H02AA02
0.1 mg
TABLET
FLUDROCORTISONE ACETATE 0.1 mg
ORAL
Prescription Only
Haupt Pharma Amareg GmbH
ACTIVE
1999-01-20
1 FLORINEF ® TABLET 0.1MG FLUDROCORTISONE ACETATE DESCRIPTION Round, uniform, biconvex, white practically odourless tablets. They are free from visible impurities. They are scored on one side and engraved on other side with “SQUIBB” and "429". FLORINEF ® tablet : Each tablet contains 0.1mg of fludrocortisone acetate and the following inactive ingredients : cornstarch, dicalcium phosphate, lactose, magnesium stearate, sodium benzoate and talc. PHARMACOLOGY The active ingredient in FLORINEF ® tablets is fludrocortisone (also known as fluo(ro)hydrocortisone or fluohydrisone) acetate, a synthetic adrenocortical steroid with potent mineralocorticoid properties and high glucocorticoid activity. It is used for its mineralocorticoid effects. Corticosteroids are thought to act, at least in part, by controlling the rate of synthesis of proteins at the cellular level. The relationship between this activity and the metabolic effects is not yet totally clear. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone but the glucocorticoid effect is 15 times as potent and the mineralocorticoid effect is 125 times greater. Sodium reabsorption in the renal distal tubules and in other tissues appears to account for the physiologic action characteristic of mineralocorticoids. Small doses of these drugs result in marked sodium retention and increased urinary excretion of potassium and hydrogen. Blood pressure is also elevated, apparently because of these effects on electrolytes. Larger doses inhibit endogenous adrenal cortical secretion, thymic activity, and pituitary corticotropin excretion; high doses also promote the deposition of liver glycogen, and, unless protein intake is adequate, induce negative nitrogen balance. The approximate half-life of fludrocortisone is 18 to 36 hou Izlasiet visu dokumentu
FLORINEF TABLET 0.1 MG FLUDROCORTISONE ACETATE DESCRIPTION Round, uniform, biconvex, white practically odourless tablets. They are free from visible impurities. They are scored on one side and engraved on other side with “FT01”. FLORINEF tablet : Each tablet contains 0.1mg of fludrocortisone acetate and the following inactive ingredients : cornstarch, dicalcium phosphate, lactose, magnesium stearate, sodium benzoate and talc. PHARMACOLOGY The active ingredient in FLORINEF tablets is fludrocortisone (also known as fluo(ro)hydrocortisone or fluohydrisone) acetate, a synthetic adrenocortical steroid with potent mineralocorticoid properties and high glucocorticoid activity. It is used for its mineralocorticoid effects. Corticosteroids are thought to act, at least in part, by controlling the rate of synthesis of proteins at the cellular level. The relationship between this activity and the metabolic effects is not yet totally clear. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone but the glucocorticoid effect is 15 times as potent and the mineralocorticoid effect is 125 times greater. Sodium reabsorption in the renal distal tubules and in other tissues appears to account for the physiologic action characteristic of mineralocorticoids. Small doses of these drugs result in marked sodium retention and increased urinary excretion of potassium and hydrogen. Blood pressure is also elevated, apparently because of these effects on electrolytes. Larger doses inhibit endogenous adrenal cortical secretion, thymic activity, and pituitary corticotropin excretion; high doses also promote the deposition of liver glycogen, and, unless protein intake is adequate, induce negative nitrogen balance. The approximate half-life of fludrocortisone is 18 to 36 hours. It is highly protein bound and is eliminated by the kidneys, mostly as inactive metabolites. Duration of action is 1 to 2 days. INDICATIONS AND USAGE FLORINEF is indicated as partial replacement therapy for primary and secondary adrenoco Izlasiet visu dokumentu